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Available online 28 September 2016Frontotemporal dementia with parkinsonism linked to chromosome 17q21.2 (FTDP-17) is an autosomal-domi-
nant neurodegenerative disorder. Mutations in the MAPT (microtubule-associated protein tau) gene can cause
FTDP-17, but the underlying pathomechanisms of the disease are still unknown. Induced pluripotent stem
cells (iPSCs) hold great promise to model FTDP-17 as such cells can be differentiated in vitro to the required
cell type. Furthermore, gene-editing approaches allow generating isogenic gene-corrected controls that can be
used as a very speciﬁc control. Here, we report the generation of genetically corrected iPSCs from a 59-year-
old female FTD-17 patient carrying an R406Wmutation in the MAPT-gene.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Resource Table:ame of stem cell
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ey transcription
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2011). This is an open access article under1. Resource details
Previously, we have generated an induced pluripotent stem cell
(iPSC) line (H237C3) froma symptomatic, 59-year-oldwoman carrying
an R406W mutation in microtubule-associated protein tau (MAPT)
gene. Reprogramming was performed by electroporation with three
episomal plasmids encoding hOCT4, hSOX2, hKLF4, hL-MYC, and
hLIN28 (Okita et al., 2011; Takahashi et al., 2007). This cell line, termed
H237 C3, has previously been described (Rasmussen et al., 2016).
We have generated a gene-corrected clone of H237 C3 using CRISPR/
Cas9 technology, where the mutated triplet TGG (tryptophan) was
corrected to the wild-type triplet CGG (arginine) using an ssODN (single
stranded oligodeoxynucleotide) as homologous template (Fig. 1A). We
conﬁrmed by sequencing analysis that the mutated triplet was corrected
without further deletions or insertions at the CRISPR cutting site (Fig. 1B).
Finally,we conﬁrmed that the cellswere still pluripotent after gene-correc-
tion (Fig. 1C, D and E) and that they showed a normal karyotype (Fig. 1F).2. Materials and methods
2.1. CRISPR design
Isogenic gene-corrected controls were obtained using the CRISPRs/
Cas9 system in combination with an ssODNs serving as homologousthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Characterization of iPSCs. (A) Schematic of the gene editing strategy used to correct the MAPT R406Wmutation in exon 13 using the CRISPR/Cas9 system in combination with an
ssODN as homologous construct. (B) Sequencing result of the original clone shows a heterozygous CNTmutation (leading to the R406Wmutation; upper panel). After gene correction, the
mutation was no longer present (lower panel). (C) Immunoﬂuorescence staining for the pluripotencymarkers OCT4 (red), TRA1-60 (green) and SSEA4 (green), scale bars = 200 μM. (D)
Quantitative PCR analysis of pluripotency genes from the gene-corrected line and a previously established iPSC control line BIONi010-C compared to ﬁbroblasts (set to 1). (E)
Immunocytochemistry for proteins representative of the three germ layers, Tuj1 (ectoderm), SMA (mesoderm) and AFP (endoderm), after in vitro differentiation by embryoid body
formation, Scale bars = 100 μM. (F) Representative karyotype of H237 C3 R406W gene-corrected iPSC (46, XX).
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Table 1
Antibodies used for immunochemistry.
Antibodies and host species Dilution
Company and catalog
number
Pluripotency Goat anti-OCT4 1:500 Santa Cruz, sc-8628
Rabbit anti-NANOG 1:100 Millipore, AB5731
Mouse anti-SSEA4 1:500 BioLegend, 330402
Mouse anti TRA-1-60 1:500 BioLegend, 330602
Mouse anti TRA-1-81 1:500 BioLegend, 330702
In vitro
differentiation
Mouse anti-smooth muscle
actin (SMA)
1:500 Dako, M0851
Rabbit
anti-Alpha-1-fetoprotein
(AFP)
1:500 Dako, A0008
Mouse anti-Beta-III-tubulin
(TUJ1)
1:500 Sigma-Aldrich, T8660
578 N. Nimsanor et al. / Stem Cell Research 17 (2016) 576–579template covering the site of the mutation. CRISPRs targeting exon
13 of the MAPT gene were designed at http://crispr.mit.edu/. The
CRISPRs were generated in a single plasmid (a gift from Feng
Zhang) containing both sgRNA and the Cas9 (pSpCas9(BB)-2A-Puro
(PX459); Addgene plasmid #62988) following the protocol from
Ann Ran (Ran et al., 2013).
2.2. Nucleofection
iPSCs were cultured on 100 mm dishes coated with Matrigel
(Corning Bioscience) in E8 medium and detached using Accutase
when they reached a density of 70–90%. A total of 1.5 × 106 cells were
co-nucleofected with 8 μg of the CRISPR/Cas9 plasmid PX459, 2 μg of a
the pEasyﬂox I plasmid with a pgk-Neo resistance cassette and 1 μL of
100 μM ssODN using the P3 Primary Cell Kit (Lonza) and program
CA167 following to the manufacturer's instructions (Lonza). iPSCs
were subsequently transferred back to a Matrigel-coated 100 mm dish
in E8medium supplemented with 1:200 diluted Revita cell supplement
(Gibco). 24 h post-nucleofection, cells were subjected to neomycin se-
lection for 4 days (2 days 100 nM and 2 days 250 nM) and allowed to
recover for a week. Resistant colonies were then picked and expanded
for genotyping.
2.3. Genotyping
DNA for genotypingwas extracted using the FlexiGene Kit (Qiagen).
PCR genotypingwas performed using TEMPase Hot Start DNA Polymer-
ase (Ampliqon) according to the manufacturer's instructions at an an-
nealing temperature of 62 °C. The following screening primers were
designed covering the R406W mutation in the MAPT gene: Exon 13
forward 5′-CTGGTCTTTCTCTGGCACTT-3′ and Exon 13 reverse 5′-
ACCAATTAACCGAACTGCG-3′. The PCR products were digested using
NcoI for 1 h to detect gene-corrected clones (correction of the mutation
leads to loss of NcoI restriction enzyme site). Positive clones were then
sequenced using the forward primer to ensure correction of the
mutation.
2.4. qRT-PCR analysis of stem cell markers
Total RNA was puriﬁed from H237 C3 GC iPSCs, ﬁbroblasts and the
iPSC line BIONi010-C (Rasmussen et al., 2014) as a positive control
using RNeasy mini kit (Qiagen, Hilden, Germany). Conversion to cDNA
was performedwith RevertAid First Strand cDNA synthesis kit (Thermo
Scientiﬁc, Waltham, MA, USA). qPCR analysis was carried out using the
TaqMan primers GAPDH Hs03929097_g1, NANOG Hs02387400_g1,
OCT4 Hs00999632_g1, TDGF1 Hs02339497_g1, DMNT3B
Hs00171876_m1 and GABRB3 Hs00241459_m1 (Thermo Scientiﬁc,
Waltham, MA, USA; International Stem Cell Banking Initiative). Data
was analyzed using the 2−ΔΔCt method relative to GAPDHwith ﬁbro-
blasts as a reference (set to 1).
2.5. In vitro differentiation
iPSCs were dissociated with EDTA (Gibco) and allowed to form
aggregates in non-coated cell culture dishes with E8 medium. On
day 2, the E8 medium was changed to E6 medium (E6 medium =
E8 medium without FGF2 and TGF-β1). On day 7, the aggregates
were transferred to matrigel-coated dishes and medium was
switched to differentiation medium. For mesodermal differentia-
tion: DMEM/F12 containing 10% FBS, 1% L-glutamine, and 1% non-
essential amino acids (all Gibco). For endodermal differentiation:
MCDB131-1 containing 0.5% BSA, 0.1% pen/strep, 3 μM CHIR99021
(Selleckchem), 100 ng/mL Activin A (Cell Guidance). For ectoder-
mal differentiation: DMEM/F12 mixed with neurobasal medium
in a ratio of 1:1, 1X B27, 1X N2, and 1% L-glutamine (all Gibco),
10 μM SB 431542 and 0.1 μM LDN 193189 (both Selleckchem).Cells were ﬁxed for immunocytochemistry on day 21. ICC analysis
was performed with the antibodies against TUJ1, SMA and AFP
(Table 1).
2.6. Immunostaining of pluripotency markers
Cells were seeded onmatrigel-coated coverslips. After 2 days, the
cells were ﬁxed at room temperature with 4% paraformaldehyde in
PBS for 10 min, permeabilized with 0.1% Triton X-100 and blocked
for unspeciﬁc binding with 2% BSA in PBS for 1 h. Immunostaining
was performed with primary antibodies against OCT4, NANOG,
TRA-1-60, TRA-1-81, and SSEA4 (Table 1). After incubation with
the primary antibody, the cells were washed 3 times with PBS and
then incubated with ﬂuorescence-conjugated secondary antibodies
Alexa ﬂuor 488 (goat anti-mouse, 1:1000) or Cyanine 3 (goat anti-
rabbit, 1:1000) for 1 h (both Life technologies). The cells were
mounted on glass slides with mounting solution-containing DAPI
(Life Technologies).
2.7. Veriﬁcation and authentication
An intact genome was demonstrated by karyotyping using G-
banding of 11 mitoses (Fig. 1F). Analysis was performed at the Insti-
tute of Medical Genetics and Applied Genomics, University of
Tübingen, Germany.
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